Q-omics provides the consensus-scored OR2T35 profile across patient tissues and cancer cell-line models. OR2T35 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, OR2T35 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, OR2T35 RNA expression shows 4,624 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight SKCM, and KIRC as cancer lineages where OR2T35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2T35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2T35 survival associations across molecular data types. OR2T35 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2T35 RNA expression–survival associations across cancer types. High OR2T35 expression shows unfavorable associations in SKCM, THYM, ESCA, CESC, LUSC and PRAD. The SKCM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for OR2T35 RNA expression.
This table summarizes OR2T35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2T35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2T35 shows lower tumor expression in KICH and higher tumor expression in KIRC. The KIRC box plot shows higher OR2T35 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p = .018).
This table shows molecular features associated with OR2T35 in patient tissues and cancer cell lines. In patient samples, OR2T35 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set. In cancer cell lines, OR2T35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Myeloma.
